Biopharmaceutical Contract Manufacturing: New Capacity and Increased Funding for Biotechnology Companies Spurs Growth.Business Editors MORAGA, Calif.--(BUSINESS WIRE)--Sept. 10, 2003 The biopharmaceutical contract manufacturing market continues to grow as funding returns to the biotechnology sector and new capacity comes online at contract manufacturing sites. In 2002, the downturn Downturn The transition point between a rising, expanding economy to a falling, contracting one. downturn A decline in security prices or economic activity following a period of rising or stable prices or activity. in the economy and numerous biopharmaceutical product failures in clinical trials caused a slight cutback cut·back n. 1. A decrease; a curtailment: "The political effects of food cutbacks could be devastating" New York Times. 2. in the number of biotechnology-based drugs being developed and some manufacturing projects were put on hold. This year, however, more biotechnology products are moving through the pipeline requiring increasingly larger volumes of production. By 2008 to 2010, commercial-scale production of at least 50 new biotechnology products will be required. The new industry study just published by HighTech Business Decisions, Biopharmaceutical Contract Manufacturing: Serving the Growing Need for Biopharmaceutical Production, reports that in 2003, the industry is in a balance of capacity and needs. Sandra Fox, president of HighTech Business Decisions, explains, "Typically, the industry goes through cycles of too little capacity versus too much. In the past few years, capacity shortages drove contractors and pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. to build biomanufacturing capacity at an unprecedented rate. The setbacks to the biotechnology community occurring in 2002, including restricted funding and some clinical trial failures, along with the newly built capacity, have brought the industry back in balance between capacity and needs. The industry will continue to grow at a measured pace as biopharmaceuticals move through the pipeline to commercial scale and the new capacity continues to come online. With the large number of biopharmaceutical products expected to reach the market in the next 5 to 10 years, however, capacity shortages may again occur." Biomanufacturing managers at pharmaceutical and biotechnology companies say that the top three reasons they outsource biomanufacturing are (1) lack of in-house capacity, (2) lack of in-house expertise and (3) a need for quick production of material. The market for biopharmaceutical contract manufacturing is expected to grow from $1.3B in 2003 to $1.7B in 2004. Major contractors providing mammalian mammalian emanating from or pertaining to mammals. cell culture or microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. fermentation fermentation, process by which the living cell is able to obtain energy through the breakdown of glucose and other simple sugar molecules without requiring oxygen. Fermentation is achieved by somewhat different chemical sequences in different species of organisms. production technologies include Abbott Bioresearch bi·o·re·search n. Research in the biological sciences. Center, Avecia Biotechnology, BioReliance Corp., Boehringer Ingelheim GmbH, Cambrex Biopharmaceutical Services, Dowpharma, GlaxoSmithKline Biopharmaceuticals, Lonza Custom Manufacturing, Diosynth-RTP, Sandoz GmbH, and DSM 1. DSM - Data Structure Manager. An object-oriented language by J.E. Rumbaugh and M.E. Loomis of GE, similar to C++. It is used in implementation of CAD/CAE software. DSM is written in DSM and C and produces C as output. Biologics. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion